"ALS/MND is a truly devastating disease. At the UK DRI, we are committed to finding new treatments and changing the lives of those affected now and in the future." Prof Bart De Strooper
UK DRI Director
1. Background
Amyotrophic Lateral Sclerosis (ALS), or Motor Neurone Disease (MND), is a fatal neurodegenerative condition that causes progressive weakness of the muscles due to the degeneration of motor neurones in the brain and spinal cord. The average age at onset is 60 years and death usually occurs three years after the first symptoms appear, due to respiratory failure. Although there are some treatments available that can slow the progression by a few months, those affected are in desperate need of more effective therapeutics that improve symptoms and extend life expectancy.
2. UK DRI priority
UK DRI is the country's leading research institute for neurodegenerative disease with world experts across the ALS/MND research spectrum. Discovery science is the engine that drives medical progress; translational research is the process by which we apply our basic science discoveries to the needs of patients; clinical research is how we test these approaches in patients.
